A systematic review and meta-analysis on safety and efficacy of Lu-177 PSMA-617 and standardized treatment in mCRPC from randomized phase II/III trials

Authors

• Rohan Garje
• Mohammad Arfat Ganiyani
• Ahmad Sheraz Iqbal
• Darwood Hasan Syed
• Arjun Pon Avudaiappan
• Adithya Nagendran, Rochester Regional HealthFollow
• Azza E A Abdalla, Rochester Regional HealthFollow
• Manas Pustake
• Gabriel Valagni
• Anisha Agarwal
• Adeel Kaiser
• Minesh P. Mehta
• Murugesan Manoharan

Department

Internal Medicine

Document Type

Conference Proceeding

Publication Title

Journal of Clinical Oncology

Conference Name

American Society of Clinical Oncology (ASCO) Annual Meeting

Conference Date

2026-05-29 - 2026-06-02

First Page

e17069

DOI

10.1200/JCO.2026.44.16_suppl.e17069

Volume

44

Issue

16_suppl

Publication Date

6-1-2026

Recommended Citation

Garje, R., Ganiyani, M. A., Iqbal, A. S., Syed, D. H., Avudaiappan, A. P., Nagendran, A., Abdalla, A. E., Pustake, M., Valagni, G., Agarwal, A., Kaiser, A., Mehta, M. P., & Manoharan, M. (2026). A systematic review and meta-analysis on safety and efficacy of Lu-177 PSMA-617 and standardized treatment in mCRPC from randomized phase II/III trials. Journal of Clinical Oncology, 44 (16_suppl), e17069. https://doi.org/10.1200/JCO.2026.44.16_suppl.e17069